RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$866M
AUM Growth
+$41.2M
Cap. Flow
-$23.2M
Cap. Flow %
-2.68%
Top 10 Hldgs %
41.18%
Holding
70
New
22
Increased
15
Reduced
16
Closed
15
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$33.3M
2
MCK icon
McKesson
MCK
+$31.1M
3
ADVM icon
Adverum Biotechnologies
ADVM
+$20.8M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$18.6M
5
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$18.1M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$37.6M
2
AGN
Allergan Inc
AGN
+$28.8M
3
ZBH icon
Zimmer Biomet
ZBH
+$26.6M
4
UHS icon
Universal Health Services
UHS
+$26.1M
5
A icon
Agilent Technologies
A
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 75.81%
2 Miscellaneous 18.86%
3 Technology 2.52%
4 Communication Services 1.66%
5 Industrials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$20.5B
$49.2M 5.68%
+450,000
New +$39.6M
2014 Q3
0 quarters
BHC icon
2
Bausch Health
BHC
$2.2B
$43.6M 5.04%
332,567
+104,737
+46% +$12.5M
2014 Q1
2 quarters
AGN
3
DELISTED
Allergan plc
AGN
$39.5M 4.57%
163,898
-12,800
-7% -$2.86M
2013 Q3
4 quarters
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$35.6M 4.11%
784,459
+60,643
+8% +$2.53M
2013 Q2
5 quarters
CELG
5
DELISTED
Celgene Corp
CELG
$35M 4.04%
+369,400
New +$33.3M
2014 Q3
0 quarters
FOLD icon
6
DELISTED
Amicus Therapeutics
FOLD
$34M 3.92%
5,706,906
-1,943,362
-25% -$10.2M
2013 Q2
5 quarters
MCK icon
7
McKesson
MCK
$114B
$31.5M 3.64%
+161,765
New +$31.1M
2014 Q3
0 quarters
CMRX icon
8
DELISTED
Chimerix, Inc.
CMRX
$31M 3.58%
1,121,032
-216,118
-16% -$5.25M
2013 Q2
5 quarters
ARRY icon
9
DELISTED
Array Biopharma Inc
ARRY
$29.8M 3.44%
8,342,045
+256,100
+3% +$1.01M
2013 Q2
5 quarters
RCPT
10
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$27.3M 3.16%
439,878
-313,782
-42% -$15M
2013 Q3
4 quarters
TRIV
11
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$25.5M 2.95%
1,751,518
+210,870
+14% +$3.06M
2014 Q2
1 quarter
RAD
12
DELISTED
Rite Aid Corporation
RAD
$25.5M 2.94%
263,036
+139,343
+113% +$18M
2014 Q1
2 quarters
HCA icon
13
HCA Healthcare
HCA
$102B
$23.2M 2.67%
328,292
-286,767
-47% -$19M
2013 Q2
5 quarters
CSLT
14
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$21.8M 2.52%
1,683,817
+519,560
+45% +$6.85M
2014 Q1
2 quarters
ADVM icon
15
DELISTED
Adverum Biotechnologies
ADVM
$21.5M 2.49%
+69,946
New +$20.8M
2014 Q3
0 quarters
MNK
16
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$20.9M 2.41%
+231,389
New +$18.1M
2014 Q3
0 quarters
GMED icon
17
Globus Medical
GMED
$10.2B
$19M 2.2%
966,300
+133,312
+16% +$2.74M
2013 Q2
5 quarters
CBST
18
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$18.8M 2.17%
+283,756
New +$18.6M
2014 Q3
0 quarters
ZSPH
19
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$18.6M 2.15%
+474,132
New +$15.7M
2014 Q3
0 quarters
NUVA
20
DELISTED
NuVasive, Inc.
NUVA
$17.4M 2.01%
498,441
-3,850
-0.8% -$137K
2013 Q2
5 quarters
TVTY
21
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$16.4M 1.9%
1,026,503
-208,268
-17% -$3.53M
2013 Q3
4 quarters
OXFD
22
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$16.3M 1.88%
1,066,415
+105,595
+11% +$1.62M
2013 Q4
3 quarters
NSTG
23
DELISTED
NanoString Technologies, Inc.
NSTG
$15.9M 1.84%
1,453,655
+319,707
+28% +$3.95M
2013 Q3
4 quarters
HNT
24
DELISTED
HEALTH NET INC
HNT
$15.4M 1.78%
+334,935
New +$14.9M
2014 Q3
0 quarters
MODN icon
25
DELISTED
MODEL N, INC.
MODN
$14.4M 1.66%
1,457,278
+96,400
+7% +$931K
2013 Q4
3 quarters
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2014 Portfolio in Review

As of Q3 2014, Redmile Group held 70 positions worth $866M, up 5% from $825M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Redmile Group's Q3 2014 filing shows 22 new, 15 increased, 16 reduced and 15 closed positions. Its largest new stake was Celgene Corp: 369,400 shares worth $35M. The largest sale was Medtronic, an estimated $37.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Technology.

  • Redmile Group's largest Q3 2014 buy was Celgene Corp: 369,400 shares worth $35M.
  • Redmile Group added most to Rite Aid Corporation in Q3 2014, an estimated $18M increase.
  • Redmile Group's biggest Q3 2014 reduction was Universal Health Services, cutting an estimated $26.1M.
  • Redmile Group fully exited Medtronic in Q3 2014, selling an estimated $37.6M.
  • Redmile Group's ten largest holdings make up 41% of its $866M portfolio in Q3 2014.
  • Redmile Group opened 22 new positions and closed 15 in Q3 2014.
  • Redmile Group's portfolio value rose 5% quarter-over-quarter to $866M.

Based on Redmile Group's 13F filing for Q3 2014, filed 14 Nov 2014.